Angelman syndrome in Poland: current diagnosis and therapy status-the caregiver perspective: a questionnaire study.
Angelman syndrome
Genetic testing
Healthcare organisation
Rase diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
10
05
2024
accepted:
23
07
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Angelman syndrome (AS) is a rare neurodevelopmental disease caused by imprinting disorders that impede the production of the ubiquitin E3A ligase protein (UBE3A). AS affects multiple systems, with the main symptoms including epilepsy, psychomotor disorders and speech development disorders. To date, no study has been conducted in the Polish population to verify the condition's diagnosis and treatment process. Seventy patients with the median age of 60 months were included into the analysis. 80% of patients were diagnosed with deletion, 19.9% with a mutation of UBE3A gene, 4.3% with paternal uniparental disomy (UPD) and 2.8% with an imprinting defect. The mean age of first symptoms was 5 months, while the mean age of diagnosis was 29 months (earliest in deletion group at 23 months), and the median duration of diagnosis process was 7 months. The average time to a clinical geneticist appointment was 3 months. 37.9% of the patients initially received a different diagnosis. Epileptic seizures were present in 88.6% of the individuals. 98.6% of the studied group were under care of a pediatric neurologist, 47.1% of a gastroenterologist. A ketogenic diet was used in 7.1% of patients. Caregivers identified finding a specialist suitable for AS patients and access to genetic testing as the biggest problems. The care of patients with AS in Poland is carried out according to the European and world standards, however there is an impeded access to clinical geneticist, and the knowledge about rare diseases among primary healthcare physicians could be improved. Moreover, access to AS care specialists and coordination of care is limited. There is a need for creation a specialized centers and databases for AS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Angelman syndrome (AS) is a rare neurodevelopmental disease caused by imprinting disorders that impede the production of the ubiquitin E3A ligase protein (UBE3A). AS affects multiple systems, with the main symptoms including epilepsy, psychomotor disorders and speech development disorders. To date, no study has been conducted in the Polish population to verify the condition's diagnosis and treatment process.
RESULTS
RESULTS
Seventy patients with the median age of 60 months were included into the analysis. 80% of patients were diagnosed with deletion, 19.9% with a mutation of UBE3A gene, 4.3% with paternal uniparental disomy (UPD) and 2.8% with an imprinting defect. The mean age of first symptoms was 5 months, while the mean age of diagnosis was 29 months (earliest in deletion group at 23 months), and the median duration of diagnosis process was 7 months. The average time to a clinical geneticist appointment was 3 months. 37.9% of the patients initially received a different diagnosis. Epileptic seizures were present in 88.6% of the individuals. 98.6% of the studied group were under care of a pediatric neurologist, 47.1% of a gastroenterologist. A ketogenic diet was used in 7.1% of patients. Caregivers identified finding a specialist suitable for AS patients and access to genetic testing as the biggest problems.
CONCLUSIONS
CONCLUSIONS
The care of patients with AS in Poland is carried out according to the European and world standards, however there is an impeded access to clinical geneticist, and the knowledge about rare diseases among primary healthcare physicians could be improved. Moreover, access to AS care specialists and coordination of care is limited. There is a need for creation a specialized centers and databases for AS patients.
Identifiants
pubmed: 39174987
doi: 10.1186/s13023-024-03292-w
pii: 10.1186/s13023-024-03292-w
doi:
Substances chimiques
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
306Informations de copyright
© 2024. The Author(s).
Références
Duis J, Nespeca M, Summers J, et al. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genom Med. 2022;10(3):1–26. https://doi.org/10.1002/mgg3.1843 .
doi: 10.1002/mgg3.1843
Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017;12(1):1–17. https://doi.org/10.1186/s13023-017-0716-z .
doi: 10.1186/s13023-017-0716-z
Guerrini R, Carrozzo R, Rinaldi R, Bonanni P. Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Pediatr Drugs. 2003;5(10):647–61. https://doi.org/10.2165/00148581-200305100-00001 .
doi: 10.2165/00148581-200305100-00001
Obersztyn E. Angelman syndrome. In: Śmigiel R, Szczałuba K, editors. Genetically conditioned developmental disorders in children. I. Warsaw: PZWL; 2021. p. 958–76.
Śmigiel R, Łukasiewicz K, Suleja A, et al. Diagnostic and therapeutic recommendations in Angelman syndrome. Pediatr Clin. 2023;31(Neurometabolism 2023):6085–92.
Krey I, Heine C, Frömming M, et al. The Angelman syndrome online registry—a multilingual approach to support global research. Eur J Med Genet. 2021;64(12):104349. https://doi.org/10.1016/J.EJMG.2021.104349 .
doi: 10.1016/J.EJMG.2021.104349
pubmed: 34619369
Napier KR, Tones M, Simons C, et al. A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry. Orphanet J Rare Dis. 2017. https://doi.org/10.1186/S13023-017-0686-1 .
doi: 10.1186/S13023-017-0686-1
pubmed: 28764722
pmcid: 5540301
Walkowiak D, Domaradzki J. Are rare diseases overlooked by medical education? Awareness of rare diseases among physicians in Poland: an explanatory study. Orphanet J Rare Dis. 2021;16(1):1–12. https://doi.org/10.1186/s13023-021-02023-9 .
doi: 10.1186/s13023-021-02023-9
Mertz LGB, Christensen R, Vogel I, et al. Angelman syndrome in Denmark. Birth incidence, genetic findings, and age at diagnosis. Am J Med Genet Part A. 2013;161(9):2197–203. https://doi.org/10.1002/AJMG.A.36058 .
doi: 10.1002/AJMG.A.36058
Bindels-de Heus KGCB, Mous SE, ten Hooven-Radstaake M, et al. An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. Am J Med Genet A. 2020;182(1):53–63. https://doi.org/10.1002/AJMG.A.61382 .
doi: 10.1002/AJMG.A.61382
pubmed: 31729827
Du X, Wang J, Li S, et al. An analysis of phenotype and genotype in a large cohort of Chinese children with Angelman syndrome. Genes (Basel). 2022. https://doi.org/10.3390/GENES13081447 .
doi: 10.3390/GENES13081447
pubmed: 36672798
pmcid: 9776370
Keute M, Miller MT, Krishnan ML, et al. Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Mol Psychiatry. 2020;26(7):3625–33. https://doi.org/10.1038/s41380-020-0858-6 .
doi: 10.1038/s41380-020-0858-6
pubmed: 32792659
pmcid: 8505254
Khan N, Cabo R, Tan WH, et al. Healthcare burden among individuals with Angelman syndrome: findings from the Angelman Syndrome Natural History Study. Mol Genet Genom Med. 2019. https://doi.org/10.1002/MGG3.734 .
doi: 10.1002/MGG3.734
Ma VK, Mao R, Toth JN, et al. Prader–Willi and Angelman syndromes: mechanisms and management. Appl Clin Genet. 2023;16:41. https://doi.org/10.2147/TACG.S372708 .
doi: 10.2147/TACG.S372708
pubmed: 37051256
pmcid: 10084876
Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med. 2010;12(7):385–95. https://doi.org/10.1097/GIM.0B013E3181DEF138 .
doi: 10.1097/GIM.0B013E3181DEF138
pubmed: 20445456
Madaan M, Mendez MD. Angelman syndrome. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK560870/ . Accessed 3 Jan 2024.
Narita K, Muramatsu H, Narumi S, et al. Whole-exome analysis of 177 pediatric patients with undiagnosed diseases. Sci Rep. 2022;12(1):1–8. https://doi.org/10.1038/s41598-022-14161-6 .
doi: 10.1038/s41598-022-14161-6
Triono A, Iskandar K, Nugrahanto AP, et al. The role of whole exome sequencing in the UBE3A point mutation of Angelman Syndrome: a case report. Ann Med Surg. 2022;73:103170. https://doi.org/10.1016/J.AMSU.2021.103170 .
doi: 10.1016/J.AMSU.2021.103170
Austin-Tse CA, Jobanputra V, Perry DL, et al. Best practices for the interpretation and reporting of clinical whole genome sequencing. npj Genom Med. 2022;7(1):1–13. https://doi.org/10.1038/s41525-022-00295-z .
doi: 10.1038/s41525-022-00295-z
Burdick KJ, Cogan JD, Rives LC, et al. Limitations of exome sequencing in detecting rare and undiagnosed diseases. Am J Med Genet A. 2020;182(6):1400–6. https://doi.org/10.1002/AJMG.A.61558 .
doi: 10.1002/AJMG.A.61558
pubmed: 32190976
pmcid: 8057342
Liu Y, Long W, Zhang Z, et al. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. World J Urol. 2021;39(11):4183–90. https://doi.org/10.1007/s00345-021-03742-1 .
doi: 10.1007/s00345-021-03742-1
pubmed: 34043023
pmcid: 8571216
Roche L, Tones M, Williams MG, et al. Caregivers report on the pathway to a formal diagnosis of Angelman syndrome: a comparison across genetic etiologies within the global Angelman Syndrome Registry. Adv Neurodev Disord. 2021;5(2):193–203. https://doi.org/10.1007/s41252-021-00195-w .
doi: 10.1007/s41252-021-00195-w
Kuenzle C, Steinlin M, Wohlrab G, et al. Adverse effects of vigabatrin in Angelman syndrome. Epilepsia. 1998;39(11):1213–5. https://doi.org/10.1111/J.1528-1157.1998.TB01314.X .
doi: 10.1111/J.1528-1157.1998.TB01314.X
pubmed: 9821987
Epilepsies in children, young people and adults. London: National Institute for Health and Care Excellence (NICE); 2022. (NICE Guideline, No. 217.). https://www.ncbi.nlm.nih.gov/books/NBK581165/ . Accessed 3 Jan 2024.
Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet. 2006;140 A(5):413–8. https://doi.org/10.1002/AJMG.A.31074 .
doi: 10.1002/AJMG.A.31074
Spruyt K, Braam W, Curfs LM. Sleep in Angelman syndrome: a review of evidence. Sleep Med Rev. 2018;37:69–84. https://doi.org/10.1016/J.SMRV.2017.01.002 .
doi: 10.1016/J.SMRV.2017.01.002
pubmed: 28784434
Trickett J, Heald M, Oliver C. Sleep in children with Angelman syndrome: parental concerns and priorities. Res Dev Disabil. 2017;69:105–15. https://doi.org/10.1016/J.RIDD.2017.07.017 .
doi: 10.1016/J.RIDD.2017.07.017
pubmed: 28844022
Bindels-de Heus KGCB, ten Hooven-Radstaake M, Legerstee JS, et al. Sleep problems in children with Angelman Syndrome: the effect of a behavioral intervention program. Res Dev Disabil. 2023. https://doi.org/10.1016/J.RIDD.2023.104444 .
doi: 10.1016/J.RIDD.2023.104444
pubmed: 36753818
Glassman LW, Grocott OR, Kunz PA, et al. Prevalence of gastrointestinal symptoms in Angelman syndrome. Am J Med Genet A. 2017;173(10):2703–9. https://doi.org/10.1002/AJMG.A.38401 .
doi: 10.1002/AJMG.A.38401
pubmed: 28816003
Thibert RL, Larson AM, Hsieh DT, et al. Neurologic manifestations of Angelman syndrome. Pediatr Neurol. 2013;48(4):271–9. https://doi.org/10.1016/J.PEDIATRNEUROL.2012.09.015 .
doi: 10.1016/J.PEDIATRNEUROL.2012.09.015
pubmed: 23498559
Leader G, Whelan S, Chonaill NN, et al. Association between early and current gastro-intestinal symptoms and co-morbidities in children and adolescents with Angelman syndrome. J Intellect Disabil Res. 2022;66(11):865–79. https://doi.org/10.1111/JIR.12975 .
doi: 10.1111/JIR.12975
pubmed: 36052644
pmcid: 9826167
Welham A, Lau J, Moss J, et al. Are Angelman and Prader–Willi syndromes more similar than we thought? Food-related behavior problems in Angelman, Cornelia de Lange, fragile X, Prader–Willi and 1p36 deletion syndromes. Am J Med Genet A. 2015;167A(3):572–8. https://doi.org/10.1002/AJMG.A.36923 .
doi: 10.1002/AJMG.A.36923
pubmed: 25691410
Salminen II, Crespi BJ, Mokkonen M. Baby food and bedtime: Evidence for opposite phenotypes from different genetic and epigenetic alterations in Prader–Willi and Angelman syndromes. SAGE Open Med. 2019. https://doi.org/10.1177/2050312118823585 .
doi: 10.1177/2050312118823585
pubmed: 30728968
pmcid: 6350130
Mertz LGB, Christensen R, Vogel I, et al. Eating behavior, prenatal and postnatal growth in Angelman syndrome. Res Dev Disabil. 2014;35(11):2681–90. https://doi.org/10.1016/J.RIDD.2014.07.025 .
doi: 10.1016/J.RIDD.2014.07.025
pubmed: 25064682
Samanta D. Epilepsy in Angelman syndrome: a scoping review. Brain Dev. 2021;43(1):32–44. https://doi.org/10.1016/J.BRAINDEV.2020.08.014 .
doi: 10.1016/J.BRAINDEV.2020.08.014
pubmed: 32893075
Michieletto P, Bonanni P, Pensiero S. Ophthalmic findings in Angelman syndrome. J AAPOS. 2011;15(2):158–61. https://doi.org/10.1016/J.JAAPOS.2010.12.013 .
doi: 10.1016/J.JAAPOS.2010.12.013
pubmed: 21596294
Giroud M, Daubail B, Khayat N, et al. Angelman Syndrome: a case series assessing neurological issues in adulthood. Eur Neurol. 2015;73(1–2):119–25. https://doi.org/10.1159/000369454 .
doi: 10.1159/000369454
pubmed: 25472600
Larson AM, Shinnick JE, Shaaya EA, et al. Angelman syndrome in adulthood. Am J Med Genet A. 2015;167A(2):331–44. https://doi.org/10.1002/AJMG.A.36864 .
doi: 10.1002/AJMG.A.36864
pubmed: 25428759
Dagli AI, Mathews J, Williams CA. Angelman Syndrome. 1998 Sep 15 [Updated 2021 Apr 22]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. https://www.ncbi.nlm.nih.gov/books/NBK1144/ . Accessed 3 Jan 2024.
Margolis SS, Sell GL, Zbinden MA, et al. Angelman syndrome. Neurotherapeutics. 2015;12(3):641–50. https://doi.org/10.1007/S13311-015-0361-Y .
doi: 10.1007/S13311-015-0361-Y
pubmed: 26040994
pmcid: 4489961
Budisteanu M, Papuc SM, Tutulan-Cunita A, et al. Angelman syndrome patient management: 5 years of clinical experience. Int J Disabil Hum Dev. 2013;12(3):379–84. https://doi.org/10.1515/IJDHD-2012-0107/MACHINEREADABLECITATION/RIS .
doi: 10.1515/IJDHD-2012-0107/MACHINEREADABLECITATION/RIS
Bonello D, Camilleri F, Calleja-Agius J. Angelman syndrome: identification and management. Neonatal Netw. 2017;36(3):142–51. https://doi.org/10.1891/0730-0832.36.3.142 .
doi: 10.1891/0730-0832.36.3.142
pubmed: 28494826
Kara OK, Mutlu A, Gunel MK, et al. Do the physiotherapy results make us happy in a case with “happy puppet” (Angelman) syndrome? BMJ Case Rep. 2010. https://doi.org/10.1136/BCR.06.2010.3081 .
doi: 10.1136/BCR.06.2010.3081
pubmed: 22802472
pmcid: 3027362
Sommese M, Corrado B. A comprehensive approach to rehabilitation interventions in patients with Angelman syndrome: a systematic review of the literature. Neurol Int. 2021;13(3):359–70. https://doi.org/10.3390/NEUROLINT13030036 .
doi: 10.3390/NEUROLINT13030036
pubmed: 34449677
pmcid: 8395863
Kiebzak W, Kowalski IM, Domagalska M, et al. Assessment of visual perception in adolescents with a history of central coordination disorder in early life—15-year follow-up study. Arch Med Sci. 2012;8(5):879–85. https://doi.org/10.5114/AOMS.2012.28638 .
doi: 10.5114/AOMS.2012.28638
pubmed: 23185199
pmcid: 3506221
Visicato LP, da Costa CSN, Taube OLS, et al. Proposal for a physical therapy program in a child with Angelman syndrome, emphasizing postural balance: a case study. Fisioter e Pesqui. 2013;20(1):70–5. https://doi.org/10.1590/S1809-29502013000100012 .
doi: 10.1590/S1809-29502013000100012
Clayton-Smith J, Adams D, Dan B et al. Angelman syndrome clinical management guidelines management of Angelman syndrome a clinical guideline Angelman syndrome clinical management guidelines, 2011. https://www.orpha.net/data/patho/Pro/en/AngelmanGuidelines2011.pdf . Accessed 21 Dec 2023.
Dwornik M, Białoszewski D, Korabiewska I, et al. Principles of neuro mobilization for treating musculoskeletal disease. Ortop Traumatol Rehabil. 2007;9(2):111–21.
pubmed: 17514163
Micheletti S, Palestra F, Martelli P, et al. Neurodevelopmental profile in Angelman syndrome: more than low intelligence quotient. Ital J Pediatr. 2016. https://doi.org/10.1186/S13052-016-0301-4 .
doi: 10.1186/S13052-016-0301-4
pubmed: 27769316
pmcid: 5073425
Buntinx IM, Hennekam RCM, Brouwer OF, et al. Clinical profile of Angelman syndrome at different ages. Am J Med Genet. 1995;56(2):176–83. https://doi.org/10.1002/AJMG.1320560213 .
doi: 10.1002/AJMG.1320560213
pubmed: 7625442
Fairbrother LC, Cytrynbaum C, Boutis P, et al. Mild Angelman syndrome phenotype due to a mosaic methylation imprinting defect. Am J Med Genet A. 2015;167(7):1565–9. https://doi.org/10.1002/AJMG.A.37058 .
doi: 10.1002/AJMG.A.37058
pubmed: 25899869
Le Fevre A, Beygo J, Silveira C, et al. Atypical Angelman syndrome due to a mosaic imprinting defect: case reports and review of the literature. Am J Med Genet Part A. 2017;173(3):753–7. https://doi.org/10.1002/AJMG.A.38072 .
doi: 10.1002/AJMG.A.38072
pubmed: 28211971
Spencer-Tansley R, Meade N, Ali F, et al. Mental health care for rare disease in the UK—recommendations from a quantitative survey and multi-stakeholder workshop. BMC Health Serv Res. 2022;22(1):1–14. https://doi.org/10.1186/s12913-022-08060-9 .
doi: 10.1186/s12913-022-08060-9
Griffith GM, Hastings RP, Oliver C, et al. Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. J Intellect Disabil Res. 2011;55(4):397–410. https://doi.org/10.1111/J.1365-2788.2011.01386.X .
doi: 10.1111/J.1365-2788.2011.01386.X
pubmed: 21323782
Kedziora S. Wpływ przewlekłej choroby dziecka na funkcjonowanie rodziny. N i S. 2007;34(36–37):57–66.
Makiełło-Jarża G. Problemy Psychologiczne Rodzin Wychowujących Dzieci Niepełnosprawne i Przewlekle Chore. In: Smoczyńska M, editor. Studia z psychologii rozwojowej i psycholingwistyki. WUJ: Cracow; 1998. p. 149–57.
Pelentsov LJ, Fielder AL, Laws TA, et al. Development of the parental needs scale for rare diseases: a tool for measuring the supportive care needs of parents caring for a child with a rare disease. J Mulidiscip Healthc. 2016. https://doi.org/10.2147/JMDH.S113898 .
doi: 10.2147/JMDH.S113898
Żelazkowska M. Wybrane metody terapii w procesie leczenia dziecka przewlekle chorego. Forum Pedagog. 2017;6(1):223–32. https://doi.org/10.21697/fp.2016.1.15 .
doi: 10.21697/fp.2016.1.15
Black N, Martineau F, Manacorda T. Diagnostic odyssey for rare diseases: exploration of potential indicators PIRU Publication 2015-13. Published online 2015. www.piru.ac.uk . Accessed 29 Jul 2023.